TipRanks (Mon, 30-Mar 7:02 AM ET)
MaxCyte Appoints New Chief Financial Officer Ahuja
TipRanks (Fri, 27-Mar 6:10 PM ET)
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access
TipRanks (Fri, 27-Mar 2:00 AM ET)
MaxCyte Earnings Call Weighs Short-Term Pain, Long-Term Upside
TipRanks (Thu, 26-Mar 8:18 PM ET)
MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook
Seeking Alpha News (Wed, 25-Mar 2:15 AM ET)
Globe Newswire (Tue, 24-Mar 4:05 PM ET)
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
Globe Newswire (Mon, 23-Mar 8:05 AM ET)
MaxCyte unveils ExPERT DTx , a 96-well electroporation platform to accelerate discovery
Globe Newswire (Tue, 24-Feb 8:05 AM ET)
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
Globe Newswire (Mon, 23-Feb 4:05 PM ET)
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Mon, 12-Jan 8:05 AM ET)
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Maxcyte trades on the NASDAQ stock market under the symbol MXCT.
As of March 30, 2026, MXCT stock price declined to $0.68 with 870,144 million shares trading.
MXCT has a beta of 1.16, meaning it tends to be more sensitive to market movements. MXCT has a correlation of 0.08 to the broad based SPY ETF.
MXCT has a market cap of $72.26 million. This is considered a Micro Cap stock.
Last quarter Maxcyte reported $7 million in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.01.
In the last 3 years, MXCT traded as high as $5.55 and as low as $.64.
The top ETF exchange traded funds that MXCT belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
MXCT has underperformed the market in the last year with a price return of -76.0% while the SPY ETF gained +12.7%. MXCT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -58.0% and -17.5%, respectively, while the SPY returned -8.2% and -4.3%, respectively.
MXCT support price is $.65 and resistance is $.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MXCT shares will trade within this expected range on the day.